血浆代谢组学与ctDNA分析在新诊断弥漫大B细胞淋巴瘤中的探索性研究
本研究在新诊断接受R-CHOP治疗的DLBCL患者中发现队列(96例)进行非靶向血浆代谢组学,并在独立验证队列(42例)中验证。2-羟基丁酸(2HB)是唯一与更差无进展生存期(PFS)相关的内源性代谢物,校正ctDNA水平后仍保持独立关联(HR 2.09,95%CI 1.04-4.19,p=0.04)。基于2HB和ctDNA的两因素预后评分改善了结局预测,可识别24个月PFS为28.8%的高危患者。
要点
- 2HB是DLBCL中与更差PFS相关的宿主相关代谢物生物标志物。
- 2HB与ctDNA联合的两因素评分优于单独ctDNA评估。
- 该评分可识别可能受益于早期再分期和治疗强化的高危患者。
核心结论
- 血浆代谢组学揭示2HB是潜在宿主相关生物标志物,可细化新诊断DLBCL的风险分层。
研究设计与样本
- 探索性研究,发现队列96例新诊断R-CHOP治疗的DLBCL患者,验证队列42例临床特征和结局可比的患者。
主要发现
- 280种已鉴定血浆代谢物均与COO分类亚型无关。
- 代谢组学谱在ctDNA定义的分子簇间呈现差异。
- 弹性网回归生存分析选出2HB为唯一与发现队列更差PFS相关的内源性代谢物,并在验证队列确认。
- 校正较高ctDNA水平(HR 2.08,95%CI 1.06-4.08,p=0.03)后,2HB水平(HR 2.09,95%CI 1.04-4.19,p=0.04)仍与更短PFS独立相关。
- 基于2HB和ctDNA的两因素预后评分改善了结局预测,识别的高危患者24个月PFS为28.8%。
关键数值与推荐
- 2HB与更差PFS独立相关:HR 2.09,95%CI 1.04-4.19,p=0.04。
- 较高ctDNA水平与更差PFS独立相关:HR 2.08,95%CI 1.06-4.08,p=0.03。
- 两因素评分识别的高危患者24个月PFS为28.8%。
临床怎么用
- 基于微创血浆生物标志物(2HB和ctDNA)的预后评分可辅助识别高危DLBCL患者。
- 高危患者可能受益于早期再分期和潜在治疗强化。
局限性
- 探索性研究,样本量有限(发现队列96例,验证队列42例)。
- 评分为假设生成性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the development of robust prognostic biomarkers for risk stratification in newly diagnosed diffuse large B-cell lymphoma (DLBCL), namely international prognostic index (IPI), cell-of-origin (COO), circulating tumor DNA (ctDNA) and molecular clusters, none of these capture potential host-related features. In this study, untargeted plasma metabolomics was performed in a discovery cohort of 96 newly diagnosed R-CHOP-treated DLBCL patients. The key finding was validated in an independent cohort of 42 DLBCL with comparable clinical characteristics and outcomes. None of the 280 identified plasma metabolites was associated with COO classification subtypes. Conversely, the metabolomic profile appeared to show variations across ctDNA-defined molecular clusters. After an elastic net regression-based survival analysis, 2-hydroxybutyric acid (2HB) was selected as the only endogenous metabolite to be associated with worse progression-free survival (PFS) in the discovery cohort. The impact of 2HB levels on PFS was confirmed in the validation cohort. Also, 2HB levels (HR 2.09, 95% CI 1.04-4.19, p=0.04) maintained an independent association with shorter PFS when adjusted for higher ctDNA levels (HR 2.08, 95% CI 1.06-4.08, p=0.03). Therefore, 2HB and ctDNA levels were included in a two-factor prognostic score based entirely on minimally invasive plasma-derived biomarkers. This hypothesis-generating score improved outcome prediction compared with ctDNA assessment alone and enabled the identification of high-risk patients who might benefit from early restaging and potential treatment intensification (24-month PFS 28.8%). In conclusion, plasma metabolomics revealed a prognostically relevant role and 2HB sorted out as a potential host-related biomarker able to refine risk stratification in newly diagnosed DLBCL.
引用
- Dondolin R, Almasri M, Marradi D, et al. Plasma metabolomics and ctDNA analysis in newly diagnosed diffuse large B-cell lymphoma: an exploratory study. Blood Adv. 2026. PMID: 42962272. doi:10.1182/bloodadvances.2026021464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。